logo-loader
viewPharmaxis Ltd

Pharmaxis advancing partnership talks for LOXL2, starting pancreatic cancer program

Pharmaxis Ltd (ASX:PXS) chief executive Gary Phillips updates Proactive Investors on the pharmaceutical research company’s key programs, including the latest on the anti fibrotic LOXL2 program which should be partnered on next year.

A partnership with Boehringer Ingelheim is progressing well, with representatives visiting Australia this week to update on Phase II Clinical Trials in diabetic retinopathy and NASH. Presentations given by Pharmaxis and Boehringer Ingelheim representatives may be found on the Pharmaxis website.

Phillips also discusses the company's latest move into pancreatic cancer.

Quick facts: Pharmaxis Ltd

Price: 0.26 AUD

ASX:PXS
Market: ASX
Market Cap: $102.61 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Pharmaxis Ltd named herein, including the promotion by the Company of Pharmaxis Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Pharmaxis hopeful of FDA approval for cystic fibrosis inhalation medicine...

Pharmaxis Ltd (ASX:PXS) chief executive officer Gary Phillips updates Proactive Investors on the FDA approval timeframe for the company’s Bronchitol inhalation medicine used to treat adult cystic fibrosis patients. The healthcare-focused company is confident it will meet information...

on 13/8/19

2 min read